Back to results
US 10,588,878 B2Granted
Solid solution compositions and use in chronic inflammation
AssigneeInfirst Healthcare Limited
InventorsRobin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
Life of this patent
Estimating the term…
Abstract
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Claims26
A solid solution pharmaceutical composition comprising:
- a) one or more propionic acid derived non-steroidal anti-inflammatory drugs (NSAIDs) in an amount of about 15% to about 40% by weight of the pharmaceutical composition;
- b) one or more pharmaceutically-acceptable hard fats comprising one or more glycerolipids, the one or more pharmaceutically-acceptable hard fats in an amount of at least 30% by weight of the pharmaceutical composition;
- c) one or more pharmaceutically-acceptable liquid lipids comprising one or more monoglycerides, the one or more pharmaceutically-acceptable liquid lipids in an amount of less than 45% by weight of the pharmaceutical composition, and
- wherein the solid solution pharmaceutical composition does not comprise a pharmaceutically-acceptable hydrophilic solvent;
- and
- wherein the solid solution pharmaceutical composition is not a multi-phasic composition.
3 more elements
A solid solution pharmaceutical composition comprising:
- a) one or more propionic acid derived non-steroidal anti-inflammatory drugs (NSAIDs) in an amount of about 25% to about 35% by weight of the pharmaceutical composition;
- b) one or more pharmaceutically-acceptable hard fats comprising one or more glycerolipids, the one or more pharmaceutically-acceptable hard fats in an amount of about 35% to about 45% by weight of the pharmaceutical composition;
- c) one or more pharmaceutically-acceptable liquid lipids comprising one or more monoglycerides, the one or more pharmaceutically-acceptable liquid lipids in an amount of about 8% to about 30% by weight of the pharmaceutical composition, and
- d) one or more liquid polyethylene glycol (PEG) polymers in an amount of about 9% to about 12% by weight of the pharmaceutical composition;
- wherein the solid solution pharmaceutical composition does not comprise a pharmaceutically-acceptable hydrophilic solvent;
- and
- wherein the solid solution pharmaceutical composition is not a multi-phasic composition.
4 more elements
A solid solution pharmaceutical composition comprising:
- a) an ibuprofen in an amount of about 25% to about 35% by weight of the pharmaceutical composition;
- b) one or more pharmaceutically-acceptable hard fats comprising one or more glycerolipids, the one or more pharmaceutically-acceptable hard fats in an amount of about 35% to about 45% by weight of the pharmaceutical composition;
- c) one or more pharmaceutically-acceptable liquid lipids comprising one or more monoglycerides, the one or more pharmaceutically-acceptable liquid lipids in an amount of about 8% to about 30% by weight of the pharmaceutical composition;
- and
- d) one or more liquid polyethylene glycol (PEG) polymers in an amount of about 9% to about 12% by weight of the pharmaceutical composition;
- wherein the solid solution pharmaceutical composition does not comprise a pharmaceutically-acceptable hydrophilic solvent;
- and
- wherein the solid solution pharmaceutical composition is not a multi-phasic composition.
5 more elements
Dependencies are inferred from the claim text.